Please use this identifier to cite or link to this item:
|Title:||Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions.|
|Citation:||Ann. Oncol..2018 May;(29)5:1130-1140|
|Abstract:||The value of induction chemotherapy (ICT) remains under investigation despite decades of research. New advancements in the field, specifically regarding the induction regimen of choice, have reignited interest in this approach for patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). Sufficient evidence has accumulated regarding the benefits and superiority of TPF (docetaxel, cisplatin, and fluorouracil) over the chemotherapy doublet cisplatin and fluorouracil. We therefore sought to collate and interpret the available data and further discuss the considerations for delivering ICT safely and optimally selecting suitable post-ICT regimens.|
|Appears in Collections:||Hospitales > H. U. Severo Ochoa > Artículos|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.